New report calls Canada’s alternative protein industry ‘hotbed of innovation and key country to do business in’
Game Changers is the first report to compile Canada’s extensive activity in alternative protein development in one place.
Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on our Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.
We have designed TPTs with the potential to offer:
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.